108 related articles for article (PubMed ID: 26952837)
1. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis.
Braun M; Qorraj M; Büttner M; Klein FA; Saul D; Aigner M; Huber W; Mackensen A; Jitschin R; Mougiakakos D
Leukemia; 2016 Aug; 30(8):1788-92. PubMed ID: 26952837
[No Abstract] [Full Text] [Related]
2. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
3. Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells.
Li S; Fan Y; Kumagai A; Kawakita E; Kitada M; Kanasaki K; Koya D
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991851
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
[TBL] [Abstract][Full Text] [Related]
5. [Level of SDF-1/CXCR4 in children with acute leukemia and its significance].
Wen Q; Chen RL; Cai KR; Lin YW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):324-6. PubMed ID: 21518481
[TBL] [Abstract][Full Text] [Related]
6. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
[TBL] [Abstract][Full Text] [Related]
7. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
[TBL] [Abstract][Full Text] [Related]
8. Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy.
Zhang Y; Chen L; Fu T; Xu A; Li K; Hao K; Lyu J; Wang Z; Kong F
ACS Appl Mater Interfaces; 2024 May; 16(17):21610-21622. PubMed ID: 38647446
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.
Fiegl M; Samudio I; Clise-Dwyer K; Burks JK; Mnjoyan Z; Andreeff M
Blood; 2009 Feb; 113(7):1504-12. PubMed ID: 18957686
[TBL] [Abstract][Full Text] [Related]
10. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination.
Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J
Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.
de Rooij B; Polak R; van den Berk LCJ; Stalpers F; Pieters R; den Boer ML
Haematologica; 2017 Oct; 102(10):e389-e393. PubMed ID: 28619846
[No Abstract] [Full Text] [Related]
12. [Advance of research on SDF-1/CXCR4 axis and angiogenesis in leukemia--review].
Bao CH; He QT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):447-51. PubMed ID: 18426684
[TBL] [Abstract][Full Text] [Related]
13. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Feng Y; Wu L
Biochem Biophys Res Commun; 2017 Feb; 483(2):897-903. PubMed ID: 28082200
[TBL] [Abstract][Full Text] [Related]
14. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
15. [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].
Zeng DF; Kong PY; Chen XH; Wei L; Chang C; Peng XG
Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):522-4. PubMed ID: 16080846
[TBL] [Abstract][Full Text] [Related]
16. CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.
Luo X; Wang X; Xia Z; Chung SK; Cheung CW
Rev Neurosci; 2016 Jan; 27(1):83-92. PubMed ID: 26353174
[TBL] [Abstract][Full Text] [Related]
17. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
[TBL] [Abstract][Full Text] [Related]
18. Trophoblast-derived chemokine CXCL12 promotes CXCR4 expression and invasion of human first-trimester decidual stromal cells.
Ren L; Liu YQ; Zhou WH; Zhang YZ
Hum Reprod; 2012 Feb; 27(2):366-74. PubMed ID: 22114110
[TBL] [Abstract][Full Text] [Related]
19. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
20. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]